Dermatology Update: The New, The Old, The Common and The Rare
Join the Derms on Drugs as we slice and dice the latest dermatology literature. We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline. We'll answer burning questions, like:-When is the best time to start niacinamide for skin cancer prevention?-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?-What can do when for PLEVA that's not responding to the usual treatments?-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?-What can you do for patients with skin involvement of systemic mastocytosis?-Are there patients who really have both atopic dermatitis AND psoriasis?-Opzelura just got approved down to age 2 - how well does it work in that age range?
--------
40:50
--------
40:50
Dermatology Update: The New, The Old, The Common and The Rare
Join the Derms on Drugs as we slice and dice the latest dermatology literature. We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline. We'll answer burning questions, like:-When is the best time to start niacinamide for skin cancer prevention?-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?-What can do when for PLEVA that's not responding to the usual treatments?-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?-What can you do for patients with skin involvement of systemic mastocytosis?-Are there patients who really have both atopic dermatitis AND psoriasis?-Opzelura just got approved down to age 2 - how well does it work in that age range?
--------
40:50
--------
40:50
Network Meta-Analyses in Dermatology: Can You Trust the Data? Expert Insights with Dr. Aaron Drucker
Ever wonder if you can trust those network meta-analyses (NMAs) flooding dermatology journals? Join the Derms on Drugs and University of Toronto expert Dr. Aaron Drucker for a critical deep dive into NMAs—what they are, how they work, and whether dermatologists should rely on them for treatment decisions.NMAs promise head-to-head comparisons for drugs without having to do a head-to-head trial, especially in psoriasis, hidradenitis suppurativa, atopic dermatitis, and soon alopecia areata. But here's the catch: different NMAs on the same topic can give conflicting results about which treatments work best.In this episode, we tackle:-What network meta-analyses actually measure and how they're conducted-Why two NMAs can reach opposite conclusions about drug effectiveness-Red flags to watch for when evaluating NMA quality and reliability-Practical guidance for incorporating NMA findings into clinical practicePerfect for dermatology providers, researchers, and pharma professionals who want to critically evaluate the evidence behind treatment guidelines. Tune in for expert analysis that might surprise you about this increasingly common research methodology.Listen now to become a smarter consumer of dermatology research! And be sure to discover more at Scholars In Medicine!
--------
46:03
--------
46:03
Rashes, Pre-cancers, and Cancers – we've got the answers!
Welcome back to Derms on Drugs! Today we’re cracking open a six-pack—not IPAs, but papers. We’ve got polyomavirus antibodies sneaking in as early markers for Merkel cell recurrence, collagen supplements promising to smooth wrinkles or just make your bank accounts smaller, and ruxolitinib cream stepping up for the disaster that is chronic hand eczema.But wait—there’s more! Isotretinoin is back, this time for seb derm instead of acne, actinic cheilitis gets the meta-analysis glow-up, lentigo maligna sees radiation face off against imiquimod, and atopic dermatitis therapies can shake up the skin microbiome, but which ones do it better?Six papers, one podcast, and probably at least three things you’ll be telling your colleagues about tomorrow. Let’s crack into it!
--------
53:54
--------
53:54
The Causes of Chronic Spontaneous Urticaria
Join the Derms on Drugs and Dr. Marc Serota (who is triple boarded in dermatology, allergy and pediatrics) to find out the latest on how to think about the causes of chronic spontaneous urticaria - it can be autoimmune, it can literally be an "allergy to yourself" or it can be neither of the above. Crucially, there are clinical clues to which one it is, and if you can figure out which one it is, it helps predict the response to therapy!So join us for a deep dive into CSU, and yes, there will be trivia at the end!Visit the Scholars In Medicine website for more.
Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology.
It's everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful.
Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.
Ireland